Here are four things to know.
1. Buprenophine for opioid use disorder was previously approved to administer in a tablet, dissolving film and implant form. Sublocade provides a new option for patients who may want to reduce the burden of taking a daily tablet.
2. Sublocade is the first monthly injectable buprenophine treatment.
3. The approval comes after an FDA advisory committee voted 18-1 that the injectable drug could benefit addicts.
4. The injection is expected to be available to US patients in the first quarter of 2018.
More articles on supply chain:
FDA: Biotin supplements may interfere with lab tests
Gilead launches hepatitis drug in China at one-fifth the US price
CVS launches ‘real-time benefits’ tool to increase price transparency
